ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Gene Therapy Experiments Get RDAC Okay

August 10, 1990

First Lady Helps Dedicate New MDA Facilities

October 15, 1976

Includes June issue of Business & Regulatory Report.

June 28, 2002

Bushes Restate Commitment to Dialogue

August 8, 2003

Oncology Groups Oppose Proposed Cuts In Medicare Payments For Cancer Drugs

October 11, 2002

Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia

October 31, 2003